

**Basingstoke, Southampton and Winchester
District Prescribing Committee**

Recommendations of the meeting of 9th October 2012

Supported or limited support, e.g. specialist recommendation/initiation

- **Adrenaline for self-administration in anaphylaxis** - The DPC supported a plan to switch over from using Epipens locally to Jextpens. Epipens have changed presentation and have a shorter shelf life than Jextpens so a managed transfer to Jextpen will bring significant savings. It was agreed that the managed transfer will have specialist leadership, careful planning and staged implementation.
- **Prucalopride Shared Care Guidelines**- there were approved for local use. The final version will be made available to local clinicians in due course, via member organisation websites.
- **Rilpivirine tablets for HIV-1 infection in adults**- The DPC supported local niche use of this agent. Rilpivirine delivers comparable efficacy to efavirenz combination therapy, at a similar cost, but with less risk of adverse events. A reminder that antivirals for treating HIV are classed as 'red' drugs locally (specialist only prescribing)
- **Iloprost IV Infusion in severe Raynauds disease with systemic sclerosis**- The DPC supported niche specialist use of iloprost for this indication. UHS has produced guidelines for appropriate use in severe disease. This treatment remains 'red' locally (specialist only prescribing). Outcome data have been requested from providers.
- **Zostavax (shingles) vaccine for recurrent herpes zoster**- National guidance from the JCVI is awaited on wider prophylactic use in older people. In small numbers of patients with recurrences (rare), this may be a useful alternative to long term aciclovir. The DPC agreed that specialist prescribing, administration and follow-up, in very small numbers of carefully selected individuals, was a reasonable option at this stage.

Not Supported currently

- **Imiquimod in the treatment of Actinic Keratosis**- This is not recommended for local use currently following a review at the August DPC meeting. The place in treatment of Actikerall solution (if any) still requires further clarification.
- **Indacaterol inhaler for COPD**- The DPC reviewed this at its August meeting, and agreed that it remains unsupported for local prescribing currently.
- **Bromfenac (NSAID) eye drops following cataract surgery**- The DPC did not recommend these for local use currently, as there is no evidence that these are better than comparator products, and they are more expensive. Current local formulary options include ketorolac eye drops, as well as corticosteroids.

Information / Reminders / Updates/ Safety Messages / NICE

- **Fampridine for the improvement of walking in multiple sclerosis**- The DPC noted the recent SHIP Priorities Committee recommendation on this, as 'low priority' for local use. In particular there was a lack of clarity of the clinical importance of the outcomes reported in the clinical studies, as well as no evidence of cost-effectiveness. The DPC considered this at its June meeting, and agreed a similar recommendation at the time.

**Summarised on behalf of the District Prescribing Committee
Julia Bowey (NHS Southampton City) 07.11.12**